Health Care

Health Care Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care

Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care Gail L. Lamoureux, BS, a dedicated and accomplished professional in the health care industry, has been honored with inclusion in Marquis Who’s Who. This Marquis prestigious recognition…

Read MoreHealth Care Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care

Vertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England

Vertex Pharmaceuticals Announces Landmark Reimbursement Agreement with NHS England, Expanding Access to CASGEVY® for Sickle Cell Disease Patients Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has revealed a significant milestone in the fight against sickle cell disease (SCD) with the announcement of…

Read MoreVertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England

Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan

TWYMEEG® Sales Performance and Forecast Update Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan A clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases characterized by metabolic pathophysiology, including metabolic…

Read MorePoxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan

BrightHeart Unveils Groundbreaking AI Results at SMFM 2025 Pregnancy Meeting, Transforming Prenatal Care

BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, recently presented two groundbreaking studies at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, which took place in Aurora, Colorado, on January 30th. These presentations,…

Read MoreBrightHeart Unveils Groundbreaking AI Results at SMFM 2025 Pregnancy Meeting, Transforming Prenatal Care

KORU Medical Systems Partners on Phase III Clinical Trial for New Nephrology Drug Indication

KORU Medical Systems Announces Strategic Collaboration for Phase III Clinical Trial on Expanded Drug Indication for Rare Renal Disorder KORU Medical Systems (NASDAQ: KRMD), a prominent medical technology company focused on innovative, patient-centric large volume subcutaneous infusion solutions, has announced…

Read MoreKORU Medical Systems Partners on Phase III Clinical Trial for New Nephrology Drug Indication

Veradigm Completes Strategic Alternatives Review and Launches Operational Assessment

Veradigm Completes Strategic Alternatives Review and Announces Operational Assessment Veradigm® (OTCMKTS: MDRX), a prominent provider of healthcare data and technology solutions, has concluded its previously announced strategic alternatives review, aimed at maximizing stockholder value. The company’s Board of Directors (the…

Read MoreVeradigm Completes Strategic Alternatives Review and Launches Operational Assessment

TROPION-Lung12 Phase 3 Trial Launches to Assess DATROWAY® in Early-Stage NSCLC Patients at High Relapse Risk

TROPION-Lung12 Phase 3 Trial Begins to Evaluate DATROWAY® as Part of Adjuvant Treatment for High-Risk Early-Stage Non-Small Cell Lung Cancer Patients Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all…

Read MoreTROPION-Lung12 Phase 3 Trial Launches to Assess DATROWAY® in Early-Stage NSCLC Patients at High Relapse Risk

Enveric Biosciences Receives Patent Approval for Lead Drug Candidate EB-003 from USPTO

Enveric Biosciences Announces Notice of Allowance for Patent on Lead Drug Candidate EB-003 Enveric Biosciences, a biotechnology firm focused on pioneering neuroplastogenic small-molecule therapeutics for mental health disorders, announced today that it has received a Notice of Allowance (NOA) from…

Read MoreEnveric Biosciences Receives Patent Approval for Lead Drug Candidate EB-003 from USPTO

Mirvie RNA Platform Identifies Unique Molecular Signal for Babies at Risk of Severe Growth Restriction

Mirvie, a leader in personalized and preventive care for pregnancy complications, recently presented groundbreaking findings at the Society for Maternal-Fetal Medicine annual meeting. The company revealed that its innovative RNA platform has identified a unique molecular signature that can predict…

Read MoreMirvie RNA Platform Identifies Unique Molecular Signal for Babies at Risk of Severe Growth Restriction
Allurion Technologies

Henry Schein Announces KKR Investment, Board Changes, and Preliminary 2025 Financial Outlook

Henry Schein Announces Strategic Investment by KKR, Board Changes, and Provides Financial Results and 2025 Guidance Henry Schein, Inc. (Nasdaq: HSIC), the world’s leading provider of health care solutions for office-based dental and medical professionals, today announced a strategic investment…

Read MoreHenry Schein Announces KKR Investment, Board Changes, and Preliminary 2025 Financial Outlook